DISCLOSURES: Nur: Novartis Pharmaceuticals: Consultancy. Maertens:Cidara: Other: Personal fees and non-financial support; Gilead Sciences: Other: Grants, personal fees and non-financial support; Amplyx: Other: Personal fees and non-financial support; Merck: Other: Personal fees and non-financial support; Pfizer: Other: Grant and personal fees; Astellas Pharma: Other: Personal fees and non-financial support; F2G: Other: Personal fees and non-financial support. Deeren:Alexion, Amgen, Janssen, Roche, Sunesis, Takeda, Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding.

doi.org/10.1182/blood-2019-124659, hdl.handle.net/1765/121593
Blood

de Jong, C., Meijer, E., Bakunina, K., Nur, E., Van Marwijk Kooij, M., de Groot, M., van Gelder, M., Maertens, J., Kuball, J., Deeren, D. (Dries), van der Holt, B., Cornelissen, J.& Broers, A. (2019). Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation: Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors. Blood, 134(1).https://doi.org/10.1182/blood-2019-124659